Advertisement

Radioprotection in Vivo: Cellular Heterogeneity and Fractionation

  • J. Denekamp
  • A. Rojas

Abstract

The curative treatment of cancer by radiotherapy is limited by the sensitivity of critical normal tissues surrounding the tumour that are inevitably included in the irradiation volume. In the last decade two new developments have progressed from the experimental stage in animals to clinical testing: Radiosensitizers that appear specific for tumour cells and radioprotectors that appear specific for normal tissues have both been developed. Of these the prototype compounds are nitroimidazole, misonidazole (miso), as a radiosensitizer (l) and the phosphorylated aminothiol WR-2721 (S-2-(3-amino-propylamino) ethyl phosphorothioic acid) as a radioprotector (2). The specificity of action of these agents does not relate to phenotypic alterations connected with the malignant transformation of cells, but rather to differences in regional oxygen tensions that result from the poor vascularity of tumours. The inadequate vascular array leads to regions of hypoxia which confer radloresistance (by a factor of 2.5 to 3.0). Miso can act as an oxygen-mimetic agent in such hypoxic regions and can repair damage from-radiation-induced radicals, a process which already occurs efficiently if oxygen is present. Miso is ineffective in oxygen. Since hypoxic cells rarely exist in normal tissues the effect is tumour-specific. Lesion repair by hydrogen donation by endogenous thiols is believed to compete with oxygen fixation of lesions, so it follows that the effect of thiols as radioprotectors is also influenced by local oxygen concentrations. Thiols are ineffective in anoxia. They are also relatively ineffective at extremely high oxygen concentrations, because the balance of the competition is loaded towards fixation. However, at oxygen tensions that are close to the transition region for radiosensitivity to radio-resistance (i.e., the K value), added thiols are maximally effective and the balance can most readily be tipped one way or the other. Since oxic cells predominate in normal tissues, the radioprotection by thiols seems to be specific for normal tissue.

Keywords

Normal Tissue Protection Factor Oxygen Tension Hypoxic Cell Thiol Content 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    G.E. Adams, J.F. Fowler and P. Wardman (Eds), Hypoxic cell sensitizers in Radiobiology and Radiotherapy. Br. J. Cancer 37 (Suppl III). (1978).Google Scholar
  2. 2.
    D.E. Davidson, M.M. Grenan, and T.R. Sweeney, Biological characteristics of some improved radioprotectors. In: Radiation Sensitizers. Their use in the clinical management of Cancer. Vol. 5 (L. W. Brady, Ed.), pp. 309–210. Masson Publishing, New York, 1980.Google Scholar
  3. 3.
    J.M. Yuhas and J.B. Storer. Differential chemoprotection of normal and malignant tissues. J. Natl. Cancer Inst. 42: 331–335 (1969).PubMedGoogle Scholar
  4. 4.
    J.M. Yuhas, J.M. Spellman, and F. Culo, The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin. Trials 3: 211–216 (1980).PubMedGoogle Scholar
  5. 5.
    T.L. Phillips, L. Kane, and J.F. Utley, Radioprotection of tumor and normal tissues by thiophosphate compounds. Cancer 32: 528–535 (1973).PubMedCrossRefGoogle Scholar
  6. 6.
    Y. Tanaka and T. Sugahara. Clinical Experiences of chemical radiation protection in tumor radiotherapy in Japan. In: Radiation Sensitizers: Their use in the clinical management of cancer (L.W. Brady, Ed.), pp. 421–425. Masson Publishing, New York, 1980.Google Scholar
  7. 7.
    M.M. Kligerraan, M.T. Shaw, M. Slavik, and J.M. Yuhas, Phase 1 clinical studies with WR-2721. Cancer Clin. Trials 3: 217–221 (1980).Google Scholar
  8. 8.
    M.M. Kllgerman, D.J. Glover, A.T. Turrisi, A.L. Norfleet, J.M. Yuhas, L.R. Cola, C. Simons, J.H. Glock, and R.L. Goodman, Toxicity of WR-2721 administered in single and multiple doses. Int. Radiat. Oncol. Biol. Phys. 10: 1773–1776 (1984).CrossRefGoogle Scholar
  9. 9.
    O.F. Nygaard and M.G. Simic (Eds.), Radioprotectors and Anticarcinogens. Academic Press, London, 1983.Google Scholar
  10. 10.
    J.D. Chapman, G.F. Whitmore (Eds.). Chemical Modifiers of Cancer Treatment. Int. J. Radiat. Oncol. Biol. Phys. 10; 1161–1813 (1984).CrossRefGoogle Scholar
  11. 11.
    J. Denekamp, A. Rojas, and F.A. Stewart, Is radioprotection by WR-2721 restricted to normal tissues? Radioprotectors and Anticarcinogens (O. Nygaard and M. Simic, Eds.), pp. 655–679. Academic Press, London, 1983.Google Scholar
  12. 12.
    J. Denekamp, Normal tissue radioprotection by WR-2721. In: Advances on Oxygen radicals and radiation protectors (A. Breccia, C.L. Greenstock, and M. Tamba, Eds.), pp. 153–171. La Scarabeo, Italy, 1984.Google Scholar
  13. 13.
    O.W. Griffith and A. Meister, Origin and turnover of mitochondrial glutathione. Proc. Natl. Acad. Sci. 82: 4668–4672 (1985).PubMedCrossRefGoogle Scholar
  14. 14.
    H. O’Hara and T. Terasima, Variations of cellular sulfhydryl content during cell cycle of HeLa cells and its correlation to cyclic change of X-ray sensitivity. Exp. Cell. Res. 58: 182–185 (1969).CrossRefGoogle Scholar
  15. 15.
    T. Alper, Cellular Radiology. Cambridge University Press, 1979.Google Scholar
  16. 16.
    J. Denekamp, B.D. Michael, A. Rojas, and F.A. Stewart, Thiol radioprotection vivo; the critical role of tissue oxygen concentration, Br. J. Radiol. 54; 1112–1114 (1981).PubMedCrossRefGoogle Scholar
  17. 17.
    C.S. Parkins, J.F. Fowler, and J. Denekamp, Low radioprotection by thiol in lung: the role of local tissue oxygenation. Eur. J. Cancer Clin. Oncol. 19: 1169–1172 (1983).PubMedCrossRefGoogle Scholar
  18. 18.
    S. Schuchhardt, Comparative physiology of the oxygen supply. In: Oxygen Supply. Theoretical and Practical Aspects of Oxygen Supply & Microcirculation of Tissue (M. Kessler, D.F. Burley, L.C. Clark, D.W. Lubbers, I.A. Silver and J. Strauss, Eds.), pp. 223–229. Urban & Schwarzenberg, Munich, 1973.Google Scholar
  19. 19.
    F.A. Stewart, J. Denekamp, and V.S. Randhawa, Skin sensitization by misonidazole; A demonstration of uniform mild hypoxia. J. Cancer 45; 869–877 (1982).CrossRefGoogle Scholar
  20. 20.
    J.H. Hendry and M.L. Sutton. Care with radio sensitizers. Radiol. 927–928 (1978).Google Scholar
  21. 21.
    A. Rojas, F.A. Stewart, J.A. Soranson, D.A. Smith, and J. Denekamp, Fractionation studies with WR-2721; Normal tissues and tumor. Radiother. Oncol. 6, 51–60 (1986).PubMedCrossRefGoogle Scholar
  22. 22.
    F.S. Echols and J.M. Yuhas. Chemoprotection against fractionated radiation exposures with WR-2721; skin injury. Radiat. Res. 66; 499–504, 1976.PubMedCrossRefGoogle Scholar
  23. 23.
    F.A. Stewart and A. Rojas, Radioprotection of mouse skin by WR-2721 in single and fractionated treatments, Br. J. Radiol. 55; 42–27 (1982).PubMedCrossRefGoogle Scholar
  24. 24.
    E.L. Travis, A.M. DeLuca, C.S. Parkins, and J.F. Fowler, Protection of early and late damage of mouse lungs by WR-2721 after single and fractionated doses of X-rays. Radiat. Res. 91: 399 (1982).Google Scholar
  25. 25.
    C.S. Parkins, J.F. Fowler, and J. Denekamp, Lung radioprotection by WR-2721 at low X-ray doses per fraction. Eur. J. Cancer Clin. Oncol. 20: 1445–50 (1984).PubMedCrossRefGoogle Scholar
  26. 26.
    M.L. Meistrich, M.V. Finch, N. Hunter, and L. Milas, Protection of spermatogonial survival and testicular function by WR-2721 against high and low doses of radiation. Int. Radiat. Oncol. Biol. Phys. 10; 2099–2107 (1984).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • J. Denekamp
    • 1
  • A. Rojas
    • 1
  1. 1.Cancer Research Campaign Gray LaboratoryMount Vernon HospitalNorthwood, MiddlesexUK

Personalised recommendations